{"schema_version":"secwatch.filing_event.v1","accession":"0001698530-26-000007","form_type":"8-K","ticker":"XCUR","cik":"0001698530","company_name":"EXICURE, INC.","filed_at":"2026-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.926091+00:00","generated_at":"2026-05-16T08:47:49.883465+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Exicure achieves Phase 2 milestone for Burixafor (GPC-100); owes $1M payment to GPCR Therapeutics","bullets":["Phase 2 trial (NCT05561751) completed; Clinical Study Report submitted to FDA on Jan 16, 2026.","Milestone payment of $1,000,000 due to GPCR Therapeutics Inc. within 30 days.","Achievement triggers improved future sublicensing income-sharing ratio for Exicure.","Milestone reflects progress in development of small-molecule CXCR4 inhibitor Burixafor (GPC-100)."],"urls":{"canonical":"https://secwatch.observer/filing/0001698530-26-000007","json":"https://secwatch.observer/filing/0001698530-26-000007.json","markdown":"https://secwatch.observer/filing/0001698530-26-000007.md","text":"https://secwatch.observer/filing/0001698530-26-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/0001698530-26-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1698530/000169853026000007/xcur-20260116.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T08:47:49.883465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}